Page 1

PHARMSTANDARD – LEADING RUSSIAN PHARMACEUTICAL COMPANY

Conference Call 28/07/11: 1H 2011 Sales Results Presentation


Key events of the first half of 2011 Company Achievements 1H 2011: •

An offer to purchase 4.9% of OJSC Pharmstandard shares

Acquisition of 55% of shares of PJSC Biolek

Increase of the Equity Capital of NauchTechStroy Plus LLC (NTS+)

Creation of Pharmstandard-Medtechnika LLC

Decisions of the Annual General Meeting of Shareholders (AGM) of 30 June 2011

Change in the status of codeine containing preparations from OTC to Rx

Sales highlights for 1H 2011: • Total growth of Company's sales for 1H 2011 achieved 59.8% or RUR 6,906.8 million. • Organic growth of Company's sales for 1H 2011 achieved 14.6% or RUR 1,109 million. •TPP sales grew by 146.5% or RUR 5,797.7 million. •Medical equipment sales increase 7.7% or 19.3 million rubles. Sales highlights for 2Q 2011: •Total growth of Company's sales in 2Q 2011 achieved 18% or RUR 1,048.8 million. • Organic growth of Company's sales in 2Q 2011 grew by 6.2% or RUR 182 million. •TPP sales grew by 30% or RUR 866.4 million. •Medical equipment sales increase 3.2% or 5.1 million rubles.

1H2011 Trade Update/Conference Call: 28.07.11

2


1H2011 Sales Structure

OTC 36.5% of Pharma sales

 Therapeutic focus:  Analgesics  Cough & cold  Vitamins  Anti-viral  Anti-fungal

Pharmaceuticals

Medical Equipment

98.5% of 1H2011 sales

1.5% of 1H2011 sales 7.7% increase

Rx 9% of Pharma sales

TPP 53.7% of Pharma sales

 Product portfolio includes:  Coronary Therapy  Acid pump inhibitors  Nitrites & nitrates  ACE inhibitors  Alimentary tract metabolism 3.2% growth

17% growth

 Product portfolio includes:  Mabthera®  Velcade ®  Pulmozym®  Others 146.5% growth

59.8% total revenue growth in 1H2011 14.6% organic revenue growth for 1H2011 1H2011 Trade Update/Conference Call: 28.07.11 * – excluding Velcade, Mildronate, IRS-19& Imudon, others products.

3


Revenue Analysis 1H 2011 Sales structure, mln RUR 20 000

18 450.2 18 000

16 000

59.8% Third parties products: + 146.5%

14 000

9 754

+ RUR 5 797.7 mln

11 543.4

12 000

10 000

3 956

+RUR 19.3 mln

72

8 000

ME: + 7.7%

144 271 1 639

252

+ RUR 50.7 mln

1 588

6 000

Rx: + 3.2%

OTC: +17.0%

4 000 6 642

5 675

+ RUR 967.0 mln

2 000

0 1H 2010 OTC

Rx

1H 2011 Medical Equipment

Others

Third parties products

Total sales grew by 59.8% Third Parties Products – 52.9% of Total Sales (1H 2010:34.3%) 1H2011 Trade Update/Conference Call: 28.07.11 Source: Company data, IFRS FS

4


Divisional Sales Breakdown 1H2011 SALES STRUCTURE

1H 2011, mln RUR

PHARMACEUTICAL PRODUCTS

% of Total sales

1H 2010, mln RUR

% of Total sales

Change 1H 2011/1H 2010, mln RUR

Change 1H 2011/1H2010, %

18,179.0

98.5%

11,291.6

97.8%

6,887.4

61.0%

PHS own OTC BRANDED NON-BRANDED PRESCRIPTION BRANDED NON-BRANDED 3rd parties products Mabtera® Velcade® Pulmozyme® IRS19® & Imudon ® Coagil VII Other 3rd parties OTHER PHARMACEUTICAL SALES MEDICAL EQUIPMENT & DISPOSABLES

8,280.7 6,641.9 5,714.7 927.2 1,638.8 1,443.3 195.5 9,754.0 4,176.8 1,650.7 819.5 623.2 623.1 1,860.7

44.9% 36.0% 31.0% 5.0% 8.9% 7.8% 1.1% 52.9% 22.6% 8.9% 4.4% 3.4% 3.4% 10.1%

7,263.0 5,674.9 4,665.0 1,009.9 1,588.1 1,351.3 236.9 3,956.3 0.0 1,649.6 610.2 122.7 790.6 783.2

62.9% 49.2% 40.4% 8.7% 13.8% 11.7% 2.1% 34.3% 0.0% 14.3% 5.3% 1.1% 6.8% 6.8%

1,017.7 967.0 1,049.7 -82.7 50.7 92.0 -41.3 5,797.7 4,176.8 1.1 209.3 500.6 -167.5 1,077.5

14.0% 17.0% 22.5% -8.2% 3.2% 6.8% -17.4% 146.5% 0.1% 34.3% 408.1% -21.2% 137.6%

144.3

0.8%

72.4

0.6%

71.9

99.4%

271.1

1.5%

251.8

2.2%

19.3

7.7%

TOTAL PHARMSTANDARD

18,450.2

100.0%

11,543.4

100.0%

6,906.8

59.8%

1H2011 Trade Update/Conference Call: 28.07.11

5


Divisional Organic Sales Breakdown 1H2011 (excluding TPP) SALES STRUCTURE

1H 2011, mln RUR

PHARMACEUTICAL PRODUCTS PHS own OTC BRANDED NON-BRANDED PRESCRIPTION BRANDED NON-BRANDED OTHER SALES MEDICAL EQUIPMENT & DISPOSABLES TOTAL PHARMSTANDARD

1H2011 Trade Update/Conference Call: 28.07.11

% of Total sales

1H 2010, mln RUR

% of Total sales

Change 1H 2011/1H 2010, mln RUR

Change 1H 2011/1H 2010, %

8,425.0

96.9%

7,335.3

96.7%

1,089.7

14.9%

8,280.7 6,641.9 5,714.7 927.2 1,638.8 1,443.3 195.5

95.2% 76.4% 65.7% 10.7% 18.8% 16.6% 2.2%

7,263.0 5,674.9 4,665.0 1,009.9 1,588.1 1,351.3 236.9

95.7% 74.8% 61.5% 13.3% 20.9% 17.8% 3.1%

1,017.7 967.0 1,049.7 -82.7 50.7 92.0 -41.3

14.0% 17.0% 22.5% -8.2% 3.2% 6.8% -17.4%

144.3

1.7%

72.4

1.0%

71.9

99.4%

271.1

3.1%

251.8

3.3%

19.3

7.7%

8,696.1

100.0%

7,587.1

100.0%

1,109.0

14.6%

6


Best Selling Brands 1H2011 (excluding TPP) 1H 2011 Volume Sales (mln № BRAND (mln packs) RUR) 1 Arbidol® 9.361 1,548 2 Pentalgin® 21.425 1,209 3 Complivit® 7.650 652 4 Therpincod® 3.353 518 5 Phosphogliv® 1.052 394 6 Codelac® 4.156 366 7 Afobazol® 2.211 342 8 Flucostat®* 2.515 312 9 Amixin®** 0.409 178 10 Biosulin® 0.324 177

1H 2010

Volume 11/10

% of total Volume (mln Sales (mln % of sales packs) RUR) total sales Change 18.7% 13.912 1,610 22.2% -4.551 14.6% 16.839 877 12.1% 4.587 7.9% 5.531 472 6.5% 2.119 6.3% 3.010 412 5.7% 0.343 4.8% 0.991 318 4.4% 0.061 4.4% 2.532 210 2.9% 1.624 4.1% 1.639 244 3.4% 0.572 3.8% 2.582 301 4.1% -0.067 2.1% 0.538 221 3.0% -0.129 2.1% 0.326 161 2.2% -0.002

Sales 11/10

% Change % -32.7% -62 -3.8% 27.2% 333 37.9% 38.3% 180 38.2% 11.4% 106 25.7% 6.2% 76 23.9% 64.1% 156 74.2% 34.9% 98 40.0% -2.6% 11 3.7% -24.0% -43 -19.6% -0.5% 16 10.2%

TOP 10 total

52.456

5,697

68.8%

47.899

4,826

66.5%

4.557

9.5%

871

18.0%

Other brands TOTAL SALES

223.191

2,583

31.2%

259.568

2,437

33.5%

-36.377

-14.0%

147

6.0%

275.647

8,281

100.0%

307.467

7,263

100.0%

-31.820

-10.3%

1,018

14.0%

Top 10 Best selling Brands demonstrated growth of 18% in value terms

1H2011 Trade Update/Conference Call: 28.07.11

7


Best Selling OTC Brands 1H 2011 (excluding TPP) 1H 2011

BRAND

1 Arbidol®

Volume (mln packs)

Sales (mln RUR)

1H 2010

% of total sales

Volume (mln packs)

Volume 11/10

Sales (mln RUR)

% of total sales

Change

%

Sales 11/10

Change

%

9.361

1,548

23.3%

13.912

1,610

28.4%

-4.551

-32.7%

-62

-3.8%

2 Pentalgin®

21.425

1,209

18.2%

16.839

877

15.5%

4.587

27.2%

333

37.9%

3 Complivit®

7.650

652

9.8%

5.531

472

8.3%

2.119

38.3%

180

38.2%

4 Therpincod®

3.353

518

7.8%

3.010

412

7.3%

0.343

11.4%

106

25.7%

5 Codelac® 6 Afobazol® 7 Flucosta®*

4.156 2.211 2.499

366 342 310

5.5% 5.1% 4.7%

2.532 1.639 2.582

210 244 301

3.7% 4.3% 5.3%

1.624 0.572 -0.083

64.1% 34.9% -3.2%

156 98 8

74.2% 40.0% 2.8%

8 Amixin®**

0.374

166

2.5%

0.449

193

3.4%

-0.075

-16.8%

-26

-13.6%

9 Acipol®

1.019

134

2.0%

0.104

12

0.2%

10 Corvalol®

19.259

119

1.8%

22.270

116

2.0%

-3.011

-13.5%

3

3.0%

TOP 10 total

71.308

5,364

80.8%

68.868

4,446

78.3%

2.440

3.5%

918

20.6%

Other brands

179.966

1,278

19.2%

212.923

1,229

21.7%

-32.957 -15.5%

49

4.0%

TOTAL SALES

251.275

6,642

100.0%

281.791

5,675 100.0%

-30.517 -10.8%

967

17.0%

1H2011 Trade Update/Conference Call: 28.07.11

0.915 880.5%

122 1034.4%

8


Products containing codeine 1H 2011 1,600

1,400

Total sales 1 209.5 1,200

17.2%

207.6 1,000

800

600

400

Total sales 517.8

42.7 200

1,001.8

Total sales 366.1 11.7%

517.8 323.4

0

Codelac®

Pentalgin® Therpincod® Containing codeine Codeine free Revenue from sales of preparations (codeine free) in 1H2011 amounted to RUR 250.3 million or 13.6% of the total sales of codeine containing preparations. Sales of Pentalgin®No.12 (codeine free) amounted to RUR 207.6 million which represented 17.2% of the total revenue from Pentalgin®. Revenue from sales of Codelac® Broncho (codeine free) amounted to RUR 42.7 million representing 11.7% of the total revenue from sales of Codelac®. 2011 1H Trade Update

9


Best Selling Rx Brands 1H 2011 (excluding TPP) 1H 2011

BRAND

Volume (mln packs)

Sales (mln RUR)

1H 2010

% of total sales

Volume (mln packs)

Sales (mln RUR)

Volume 11/10 % of total sales

Change

%

Sales 11/10

Change

%

1 Phosphogliv®

1.052

394

24.1%

0.991

318

20.0%

0.061

6.2%

76

23.9%

2 Biosulin®

0.324

177

10.8%

0.326

161

10.1%

-0.002

-0.5%

16

10.2%

3 Combilipen®

1.664

168

10.3%

1.228

117

7.4%

0.436

35.5%

51

43.8%

4 Rastan®

0.088

113

6.9%

0.221

301

19.0%

-0.133

-60.0%

5 Picamilon

1.821

78

4.7%

1.697

65

4.1%

0.124

7.3%

6 Аzitrox®

0.426

73

4.4%

0.187

30

1.9%

0.239

127.3%

7 Octolipen®

0.353

72

4.4%

0.192

36

2.3%

0.160

83.3%

8 Cyclodol

1.175

54

3.3%

1.367

61

3.8%

-0.191

-14.0%

-7 -11.1%

9 Cocarboxylase

1.022

49

3.0%

2.396

111

7.0%

-1.374

-57.3%

-62 -56.1%

1.087

47

2.9%

1.157

45

2.8%

-0.069

-6.0%

2

4.0%

78.3%

-0.748

-7.7%

-19

-1.6%

21.7%

-0.554

-3.5%

70

20.4%

100.0%

-1.303

-5.1%

51

3.2%

10 Sulphocamfocain TOP 10 total

9.014

1,225

74.7%

Other brands

15.359

414

25.3%

15.914

TOTAL SALES

24.373

100.0%

25.676

1,639

9.762 1,244 344 1,588

-188 -62.5% 13

20.1%

43 146.4% 36

99.3%

Рост рецептурных препаратов (за исключением Растана®) составил 18,6% в сравнении с первым полугодием 2010 года. По препарату Растан® в первом полугодии 2011 года государственные закупки не проводились, планируются во втором полугодии. 1H2011 Trade Update/Conference Call: 28.07.11

10


Collaboration projects – TPP (3rd parties products) Third parties products Mabthera® Velcade® Pulmozym® IRS®-19, Imudon® Coagil VII Prezista® Midronate® Intelence® Others TPP Total

Status RX RX RX OTC RX RX RX RX OTC\RX

1H 2011 % of total RUR mln sales 4,176.8 42.8% 1,650.7 16.9% 819.5 8.4% 623.2 6.4% 623.1 6.4% 612.8 6.3% 455.9 4.7% 183.3 1.9% 608.7 6.2% 9,754.0 100.0%

1H 2010 % of total RUR mln sales 0.0 0.0% 1,649.6 41.7% 610.2 15.4% 122.7 3.1% 790.6 20.0% 0.0 0.0% 554.7 14.0% 0.0 0.0% 228.4 5.8% 3,956.3 100.0%

Change RUR mln 4,176.8 1.1 209.3 500.6 -167.5 612.8 -98.9 183.3 380.3 5,797.7

% 0.1% 34.3% 408.1% -21.2% -17.8% 166.5% 146.5%

The sales of third party products have grown by 146.5% or RUR 5.797 million and reached RUR 9.754 million. The share of TPP in the overall structure of the Company's sales in 1H2011 was 52.9%.

1H2011 Trade Update/Conference Call: 28.07.11

11


Collaboration projects – TPP (3rd parties products) Third parties products

Description

XXX

XXX

Production under the contract terms completed

1650.7

XXX

XXX

819.5

XXX

XXX

623.2

XXX

XXX

623.1

XXX

XXX

Supplied under state open Manufacturing & Open auctions auctions 50% completed

612.8

Next supply under state open auctions 2H2011

612.8

Manufacturing & Distribution Sales under the contract & Sales terms completed

455.9

XXX

XXX

183.3

Next supply under state open auctions 2H2011

195.6

608.7

XXX

XXX

Velcade®

Johnson & Johnson

Manufacturing

Pulmozym®

Hoffmann-La Roche

Open auctions

IRS®-19, Imudon®

Abbott Products

Manufacturing & Sales

Coagil VII

Generium\Lekko

Open auctions & Marketing

Midronate®

Grindex

Status for the RUR mln 2H2011

4176.8

F.Hoffmann-La Roche Manufacturing & Open auctions

Johnson & Johnson

RUR mln

Supplied under state open auctions completed

Mabthera®

Prezista®

Status for the 1H2011

Supplied under state open auctions completed Production under the contract terms completed Supplied under state open auctions completed

Supplied under state open auctions 50% completed

Intelence®

Johnson & Johnson

Manufacturing & Open auctions

Others TPP

around 10 products

Manufacturing & Open auctions Sales under the contract Distribution & Sales terms completed

Total:

9754.0 1H2011 Trade Update/Conference Call: 28.07.11

12


2Q2011 Sales results

1H2011 Trade Update/Conference Call: 28.07.11

13


2Q 2011 Sales Structure

OTC 31.4% of Pharma sales

Pharmaceuticals

Medical Equipment

97.6% of 2Q2011 sales

2.4% of 2Q2011 sales 3.2% increase

Rx 10.5% of Pharma sales

 Therapeutic focus:  Analgesics  Cough & cold  Vitamins  Anti-viral  Anti-fungal

 Product portfolio includes:  Coronary Therapy  Acid pump inhibitors  Nitrites & nitrates  ACE inhibitors  Alimentary tract metabolism - 6.6% growth

11.1% growth

TPP 54.6% of Pharma sales

 Product portfolio includes:  Mabthera®  Velcade ®  Pulmozym®  Others 30% growth

18% total revenue growth in 2Q2011 6.2% organic revenue growth for 2Q2011 1H2011 Trade Update/Conference Call: 28.07.11 * – excluding Velcade, Mildronate, IRS-19& Imudon, others products.

14


Revenue Analysis 2Q 2011 Sales structure, mln RUR 8 000

6 865.1

7 000

18.0% 5 816.3

6 000

Third parties products: + 30.0% 5 000

3 751

+ RUR 866.4 mln

2 884 4 000

3 000

ME: + 3.2%

71

58

+RUR 5.1 mln

165

159

720

771

- RUR 50.6 mln

2 000

1 000

Rx: - 6.6%

2 158

1 943

OTC: + 11.1% + RUR 214.8 mln

0 2Q 2010 OTC

Rx

2Q 2011 Medical Equipment

Others

Third parties products

Total sales grew by 18.0% Third Parties Products – 54.6% of Total Sales (2Q 2010: 49.6%) 1H2011 Trade Update/Conference Call: 28.07.11 Source: Company data, IFRS FS

15


Divisional Sales Breakdown 2Q 2011 SALES STRUCTURE

2Q 2011, mln RUR

% of Total sales

2Q 2010, mln RUR

% of Total sales

Change 2Q 2011/2Q 2010, mln RUR

Change 2Q 2011/2Q 2010, %

PHARMACEUTICAL PRODUCTS

6,700.5

97.6%

5,656.9

97.3%

1,043.7

18.4%

PHS own OTC BRANDED NON-BRANDED PRESCRIPTION BRANDED NON-BRANDED 3rd parties products Velcade® Prezista® IRS19® & Imudon ® Mabtera® Mildronate® Other 3rd parties OTHER PHARMACEUTICAL SALES MEDICAL EQUIPMENT & DISPOSABLES

2,878.4 2,158.0 1,786.8 371.2 720.4 616.9 103.4 3,750.8 1,650.7 612.8 365.4 324.6 192.5 604.8

41.9% 31.4% 26.0% 5.4% 10.5% 9.0% 1.5% 54.6% 24.0% 8.9% 5.3% 4.7% 2.8% 8.8%

2,714.2 1,943.2 1,509.8 433.5 770.9 643.0 127.9 2,884.4 1,649.6 0.0 0.0 0.0 191.6 1,043.1

46.7% 33.4% 26.0% 7.5% 13.3% 11.1% 2.2% 49.6% 28.4% 0.0% 0.0% 0.0% 3.3% 17.9%

164.2 214.8 277.1 -62.3 -50.6 -26.1 -24.5 866.4 1.1 612.8 365.4 324.6 0.8 -438.4

6.0% 11.1% 18.4% -14.4% -6.6% -4.1% -19.1% 30.0% 0.1% 0.4% -42.0%

71.4

1.0%

58.3

1.0%

13.1

22.4%

164.6

2.4%

159.4

2.7%

5.1

3.2%

TOTAL PHARMSTANDARD

6,865.1

100.0%

5,816.3

100.0%

1,048.8

18.0%

1H2011 Trade Update/Conference Call: 28.07.11

16


Divisional Organic Sales Breakdown 2Q2011 (excluding TPP) SALES STRUCTURE

2Q 2011, mln RUR

PHARMACEUTICAL PRODUCTS PHS own OTC BRANDED NON-BRANDED PRESCRIPTION BRANDED NON-BRANDED OTHER SALES MEDICAL EQUIPMENT & DISPOSABLES TOTAL PHARMSTANDARD

1H2011 Trade Update/Conference Call: 28.07.11

% of Total sales

2Q 2010, mln RUR

% of Total sales

Change 2Q 2011/2Q 2010, mln RUR

Change 2Q 2011/2Q 2010, %

2,949.8

94.7%

2,772.5

94.6%

177.3

6.4%

2,878.4 2,158.0 1,786.8 371.2 720.4 616.9 103.4

92.4% 69.3% 57.4% 11.9% 23.1% 19.8% 3.3%

2,714.2 1,943.2 1,509.8 433.5 770.9 643.0 127.9

92.6% 66.3% 51.5% 14.8% 26.3% 21.9% 4.4%

164.2 214.8 277.1 -62.3 -50.6 -26.1 -24.5

6.0% 11.1% 18.4% -14.4% -6.6% -4.1% -19.1%

71.4

2.3%

58.3

2.0%

13.1

22.4%

164.6

5.3%

159.4

5.4%

5.1

3.2%

3,114.3

100.0%

2,931.9

100.0%

182.4

6.2%

17


Best Selling Brands 2Q2011 (excluding TPP) 2Q 2011

2Q 2010

Volume 2Q11/2Q10 Sales 2Q11/2Q10

Volume Sales (mln % of total Volume (mln Sales (mln % of № BRAND (mln packs) RUR) sales packs) RUR) total sales Change 1 Pentalgin® 11.647 653 22.7% 8.863 429 15.8% 2.784 2 Therpincod® 2.032 311 10.8% 1.515 194 7.2% 0.517 3 Codelac® 1.794 157 5.5% 1.628 131 4.8% 0.166 4 Phosphogliv® 0.384 146 5.1% 0.462 134 5.0% -0.078 5 Complivit® 1.321 133 4.6% 1.343 109 4.0% -0.023 6 Afobazol® 0.790 120 4.2% 0.725 101 3.7% 0.066 7 Flukostat® 0.811 100 3.5% 1.082 117 4.3% -0.271 8 Biosulin® 0.169 91 3.2% 0.163 76 2.8% 0.006 9 Kombilipen® 0.812 81 2.8% 0.673 60 2.2% 0.139 10 Corvalol® 9.168 55 1.9% 8.607 44 1.6% 0.561

% Change 31.4% 224 34.2% 116 10.2% 26 -16.9% 11 -1.7% 24 9.1% 18 -25.1% -16 3.9% 15 20.6% 21 6.5% 11

% 52.2% 60.0% 20.0% 8.2% 21.9% 18.1% -14.0% 19.3% 35.0% 26.0%

TOP 10 total

28.928

1,846

64.1%

25.060

1,395

51.4%

3.868

15.4%

450

32.3%

Other brands TOTAL SALES

86.580

1,033

35.9%

120.574

1,319

48.6%

-33.993

-28.2%

-286

-21.7%

115.509

2,878

100.0%

145.634

2,714

100.0%

-30.125

-20.7%

164

6.0%

1H2011 Trade Update/Conference Call: 28.07.11

18


Best Selling OTC Brands 2Q2011 (excluding TPP) 2Q 2011

BRAND

1 Pentalgin®

Volume (mln packs)

Sales (mln RUR)

2Q 2010

% of total sales

Volume (mln packs)

Volume 2Q11/2Q10 Sales 2Q11/2Q10

Sales (mln RUR)

% of total sales

Change

%

Change

%

11.647

653

30.2%

8.863

429

22.1%

2.784

31.4%

224

52.2%

2 Therpincod®

2.032

311

14.4%

1.515

194

10.0%

0.517

34.2%

116

60.0%

3 Codelac®

1.794

157

7.3%

1.628

131

6.7%

0.166

10.2%

26

20.0%

4 Complivit® 5 Afobazol® 6 Flucostat® 7 Corvalol®

1.321 0.790 0.795 9.168

133 120 97 55

6.2% 5.5% 4.5% 2.6%

1.343 0.725 1.082 8.607

109 101 117 44

5.6% 5.2% 6.0% 2.3%

-0.023 0.066 -0.286 0.561

-1.7% 9.1% -26.5% 6.5%

24 18 -19 11

21.9% 18.1% -16.4% 26.0%

8 Acipol®

0.337

43

2.0%

0.104

12

0.6%

0.233 224.1%

32

268.5%

9 Rinostop®

2.792

40

1.9%

2.277

25

1.3%

0.515

22.6%

15

61.9%

10 Askofen®P

6.463

38

1.8%

5.868

32

1.7%

0.595

10.1%

6

18.4%

TOP 10 total

37.140

1,647

76.3%

32.012

1,194

61.4%

5.128

16.0%

454

38.0%

Other brands

65.792

511

23.7%

99.836

750

38.6%

-34.044 -34.1%

-239

-31.9%

102.932

2,158

100.0%

131.848

1,943 100.0%

-28.915 -21.9%

215

11.1%

TOTAL SALES

1H2011 Trade Update/Conference Call: 28.07.11

19


Best Selling Rx Brands 2Q 2011 (excluding TPP) 2Q 2011

BRAND

Volume (mln packs)

2Q 2010

Sales (mln RUR)

% of total Volume sales (mln packs)

Volume 2Q11/2Q10 Sales 2Q11/2Q10

Sales (mln RUR)

% of total sales Change

%

Change

%

1 Phosphogliv®

0.384

0

0.0%

0.462

134

17.4%

-0.078

-16.9%

2 Biosulin®

0.169

91

12.6%

0.163

76

9.9%

0.006

3.9%

15

19.3%

3 Combilipen®

0.812

81

11.2%

0.673

60

7.8%

0.139

20.6%

21

35.0%

4 Pikamilon®

0.715

31

4.2%

0.674

24

3.2%

0.042

6.2%

6

25.5%

5 Octolipen®

0.148

30

4.2%

0.114

20

2.6%

0.034

29.8%

10

52.0%

6 Cyclodol

0.645

29

4.1%

0.738

30

3.9%

-0.093

-12.6%

0

-1.0%

7 Sulphocamfocain

0.601

25

3.5%

0.613

23

3.0%

-0.012

-2.0%

2

8.7%

8 Cocarboxylase

0.552

25

3.5%

1.168

61

7.9%

-0.616

-52.7%

-36

-58.6%

9 Аzitrox®

0.151

25

3.4%

0.112

17

2.2%

0.039

34.4%

8

48.1%

10 Artrozan®

0.164

23

3.2%

0.062

7

1.0%

0.102

164.4%

15 209.3%

TOP 10 total

4.341

360

50.0%

4.779

453

58.8%

-0.439

-9.2%

-93 -20.5%

Other brands

8.235

360

50.0%

9.007

318

41.2%

-0.772

-8.6%

42

13.3%

12.576

720

100.0%

13.787

100.0%

-1.210

-8.8%

-51

-6.6%

TOTAL SALES

1H2011 Trade Update/Conference Call: 28.07.11

771

-134 -100.0%

20


2Q 2011Collaboration projects – TPP (3rd parties products) Third parties products Velcade® Prezista® IRS®-19, Imudon® Mabthera® Mildronate® Intelence® Coagil VII Pulmozym® Others TPP Total

Status RX RX OTC RX RX RX RX RX

1H2011 Trade Update/Conference Call: 28.07.11

2Q 2011 % of total RUR mln sales 1,650.7 44.0% 612.8 16.3% 365.4 9.7% 324.6 8.7% 192.5 5.1% 183.3 4.9% 20.5 0.5% 6.1 0.2% 394.8 10.5% 3,750.8 100.0%

2Q 2011 % of total RUR mln sales 1,649.6 57.2% 0.0 0.0% 0.0 0.0% 0.0 0.0% 191.6 6.6% 0.0 0.0% 576.6 20.0% 366.1 12.7% 100.3 3.5% 2,884.4 100.0%

Change RUR mln 1.1 612.8 365.4 324.6 0.8 183.3 -556.1 -360.1 294.5 866.4

% 0.1% 0.4% -96.4% -98.3% 293.4% 30.0%

21


Disclaimer and Confidentiality Requirements This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of OJSC Pharmstandard (the “Company”) or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation has been prepared solely for use in connection with the possible offering of ordinary shares (the “Shares”) and global depositary receipts representing shares (“GDRs” and, together with the Shares, the “Securities”) in the Company (the “Offering”). This document is an advertisement and not a prospectus and any purchase of Securities in the Offering should be made solely on the basis of information contained in the prospectus and any supplemental prospectus to be published in respect of the Offering. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of Augment Investments Limited (the “Selling Shareholder”) or the Company or any of their respective affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. This presentation is only for persons having professional experience in matters relating to investments and must not be acted or relied on by persons who are not Relevant Persons (as defined below). Solicitations resulting from this presentation will only be responded to if the person concerned is a Relevant Person. This presentation is not for distribution in, nor does it constitute an offer of securities in the United States, Canada, Australia or Japan. Neither the presentation nor any copy of it may be transmitted into the United States, its territories or possessions, or distributed, directly or indirectly, in the United States, its territories or possessions. Any failure to comply with this restriction may constitute a violation of US securities laws. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. The Company has not registered and does not intend to register any portion of the Offering in the United States or to conduct a public offering of any securities in the United States. This presentation is made to and directed only at (i) persons outside the United Kingdom, (ii) qualified investors or investment professionals falling within Article 19(5) and Article 49(2) (a) to (d) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (such persons collectively being referred to as "Relevant Persons"). This presentation and its contents are confidential and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person, whether or not such person is a Relevant Person. Failure to comply with this restriction may constitute a violation of applicable securities laws. If you have received this presentation and you are not a Relevant Person you must return it immediately to the Company. This presentation does not constitute a recommendation regarding the securities of the Company. This presentation is not a public offer or advertisement of Securities in the Russian Federation and is not an invitation to make offers to purchase any Securities in the Russian Federation, and must not be passed on to third parties or otherwise be made publicly available in Russia. The GDRs have not been and will not be registered in Russia and are not intended for “placement” or “circulation” in Russia. This presentation includes 'forward-looking statements'. These statements contain the words "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company’s financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's projects and services) are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this presentation. Each of the Company and the Selling Shareholder and their respective agents, employees and advisers, expressly disclaims any obligation or undertaking to update any forward-looking statements contained herein. The information and opinions contained in this document are provided as at the date of this presentation and are subject to change without notice. All information not separately sourced is from Company data.

1H2011 Trade Update/Conference Call: 28.07.11

22


Contacts JSC Pharmstandard Likhachevsky drive, 5 «B» Moscow region, Dolgoprudny, Russia, 141700. Tel/Fax: (495) 970-0030/32 Ilya Krylov IR manager ex.2416 IR@pharmstd.ru www.pharmstd.ru

1H2011 Trade Update/Conference Call: 28.07.11

23

/20111htradeupdate280711  

http://pharmstd.com/news3files/20111htradeupdate280711.pdf

Read more
Read more
Similar to
Popular now
Just for you